Gain Therapeutics Inc Stock News

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of 21 participants in Phase 1b study evaluating GT-02287 in Parkinson's Disease with or without GBA1 mutations during 3Q 2025 Received approval from the Australian health authorities to extend the dur...

Gain Therapeutics achieved functional improvement in Parkinson's patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287's mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX's $66 million market cap is seen as deeply undervalued given positive trial data, large mar...

BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the Society for Neuroscience annual meeting, Neuroscience 2025, being held November 15th–19th in San...

BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it will participate in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC.

BETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule therapies, today announced that it will host a virtual key opinion leader (KOL) event, “Biomarkers, Clinical Endpoints, and the Path to Disease Modific...

Improvement observed in MDS-UPDRS scores in first 9 participants enrolled; 90-day follow-up continuing in remaining participants

BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric, small-molecule therapies, today announced that Dr. Rinaldo Montalvão, Director of Artificial Intelligence at Gain Therapeutics, will deliver a talk at the WORLD BI s...

Extension of the Phase 1b study will allow participants to continue dosing with GT-02287 for an additional nine months after completing the first 90-day dosing schedule